129 related articles for article (PubMed ID: 9071816)
1. Clinical significance of serum soluble interleukin-2 receptor in chronic myeloproliferative disorders.
Kawatani T; Endo A; Tajima F; Ooi S; Kawasaki H
Int J Hematol; 1997 Feb; 65(2):123-8. PubMed ID: 9071816
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis.
Motoi T; Uchiyama T; Hori T; Itoh K; Uchino H; Ueda R
Blood; 1989 Aug; 74(3):1052-7. PubMed ID: 2787681
[TBL] [Abstract][Full Text] [Related]
3. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.
Panteli KE; Hatzimichael EC; Bouranta PK; Katsaraki A; Seferiadis K; Stebbing J; Bourantas KL
Br J Haematol; 2005 Sep; 130(5):709-15. PubMed ID: 16115126
[TBL] [Abstract][Full Text] [Related]
4. Clinical Correlates and Prognostic Significance of IL-8, sIL-2R, and Immunoglobulin-Free Light Chain Levels in Patients with Myelofibrosis.
Barabanshikova MV; Dubina IA; Lapin SV; Morozova EV; Vlasova JJ; Ivanova MO; Moiseev IS; Afanasyev BV
Oncol Res Treat; 2017; 40(10):574-578. PubMed ID: 28946149
[TBL] [Abstract][Full Text] [Related]
5. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
6. [ATP and ADP of platelets in chronic myeloproliferative disorders and multiple myeloma].
Terada H; Ohshima M
Rinsho Ketsueki; 1989 Jan; 30(1):22-8. PubMed ID: 2716195
[TBL] [Abstract][Full Text] [Related]
7. Evidence from molecular genetic and cytogenetic analyses that bone marrow histopathology is reliable in the diagnosis of chronic myeloproliferative disorders.
Werner M; Kaloutsi V; Kausche F; Buhr T; Georgii A
Virchows Arch B Cell Pathol Incl Mol Pathol; 1993; 63(4):199-204. PubMed ID: 8099457
[TBL] [Abstract][Full Text] [Related]
8. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Beguin Y; Lampertz S; De Groote D; Igot D; Malaise M; Fillet G
Leukemia; 1993 Dec; 7(12):2019-25. PubMed ID: 8255102
[TBL] [Abstract][Full Text] [Related]
10. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
[TBL] [Abstract][Full Text] [Related]
11. Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders.
Tatewaki W; Takahashi H; Shibata A
Clin Lab Haematol; 1988; 10(4):417-25. PubMed ID: 3150698
[TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin-2 receptors in plasma cell dyscrasias.
Takamatsu T; Yasuda N; Ohno T; Kanoh T; Uchino H; Fujii H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):749-55. PubMed ID: 2618549
[TBL] [Abstract][Full Text] [Related]
13. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
15. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
16. [Megakaryopoiesis in chronic myeloproliferative disorders].
Nagasawa T
Rinsho Ketsueki; 1993 May; 34(5):551-6. PubMed ID: 8315826
[TBL] [Abstract][Full Text] [Related]
17. Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity.
He L; Shu X; Liu X; Ge Y; Li S; Lu X; Wang G
Mediators Inflamm; 2020; 2020():6243019. PubMed ID: 32774147
[TBL] [Abstract][Full Text] [Related]
18. Megakaryocytes in chronic myeloproliferative disorders: numerical density correlated between different entities.
Kaloutsi V; Fritsch RS; Buhr T; Restrepo-Specht I; Widjaja W; Georgii A
Virchows Arch A Pathol Anat Histopathol; 1991; 418(6):493-7. PubMed ID: 2058083
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection.
Sawayama Y; Hayashi J; Kawakami Y; Furusyo N; Ariyama I; Kishihara Y; Ueno K; Kashiwagi S
Dig Dis Sci; 1999 Jan; 44(1):163-9. PubMed ID: 9952238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
